Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

4.25
-0.0900-2.07%
Post-market: 4.250.00000.00%19:30 EDT
Volume:4.32M
Turnover:18.13M
Market Cap:366.40M
PE:-1.13
High:4.40
Open:4.32
Low:4.10
Close:4.34
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.49
T/O Rate:7.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.20
PE(LYR):-1.34

Loading ...

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
May 18

EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials

TIPRANKS
·
May 14

EyePoint's late-stage eye drug trials to continue after safety panel review

Reuters
·
May 14

EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review

MT Newswires Live
·
May 14

EyePoint Advances DURAVYU Phase 3 Wet AMD Program

TIPRANKS
·
May 14

EyePoint Inc - Dsmc Recommends Phase 3 Duravyu Wet Amd Trials Continue With No Modifications

THOMSON REUTERS
·
May 14

EyePoint Inc - Interim Phase 3 Data Shows Continued Favorable Safety Profile for Duravyu

THOMSON REUTERS
·
May 14

EyePoint Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu™, Building Confidence Ahead of Mid-2026 Topline Data

THOMSON REUTERS
·
May 14

EyePoint Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 08

RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating

MT Newswires Live
·
May 07

EyePoint Pharmaceuticals (EYPT) Gets a Buy from Guggenheim

TIPRANKS
·
May 07

EyePoint reports Q1 EPS (99c), consensus (81c)

TIPRANKS
·
May 07

Analysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BeOne Medicines (ONC)

TIPRANKS
·
May 07

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT) and 908 Devices (MASS)

TIPRANKS
·
May 07

EyePoint Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 06

Earnings Flash (EYPT) EyePoint Posts Q1 Loss $0.99 a Share, vs. FactSet Est of $0.79 Loss

MT Newswires Live
·
May 06

EyePoint Pharmaceuticals Q1 net loss widens on increased R&D spending

Reuters
·
May 06

EyePoint Q1 FY26 net loss widens to $84.8 million; revenue drops to $0.7 million

Reuters
·
May 06

EyePoint Pharmaceuticals Q1 EPS $(0.99) Misses $(0.80) Estimate, Sales $696.000K Beat $352.833K Estimate

Benzinga Earnings
·
May 06

EyePoint Pharmaceuticals Q1 Basic EPS USD -0.99

THOMSON REUTERS
·
May 06